Global adoption of COVID-19 early treatments

Treatment	Improvement   (early)	Studies   (early)	China	India	USA	Indonesia	Pakistan	Brazil	Nigeria	Bangladesh	Russia	Mexico	Japan	Ethiopia	Philippines	Egypt	Vietnam	DR Congo	Germany	Iran	Turkey	Thailand	United Kingdom	France	Italy	South Africa	Kenya	Myanmar	Colombia	South Korea	Spain	Uganda	Argentina	Algeria	Sudan	Ukraine	Iraq	Afghanistan	Canada	Poland	Morocco	Saudi Arabia	Angola	Peru	Uzbekistan	Malaysia	Ghana	Mozambique	Yemen	Nepal	Madagascar	Venezuela	Cameroon	Australia	Côte d'Ivoire	Niger	Taiwan
AMAmubarv../r..	91%	1
EVEnsovibep	89%	1
BHBromhexine	84%	2
CHXChlorhexidine	79%	1
MTMelatonin	78%	2
SPSpironolactone	77%	1
PHAlkalinization	75%	3
PXProxalutamide	71%	3
AAspirin	67%	1
(H)CQHydroxychlor..	66%	39
SBSodium Bicarb..	65%	1
PIPovidone-Iod..	63%	15
RGRegdanvimab	62%	10
V.AVitamin A	62%	3
IVMIvermectin	61%	40
V.DVitamin D	60%	11
MFMetformin	58%	3
H1RAH1RA	56%	3
CPMChlorpheniramine	56%	3
BLBamlaniv../e..	52%	15
BUBudesonide	49%	2
FMFamotidine	48%	1
FVFluvoxamine	48%	12
LFLactoferrin	47%	3
CICasirivimab/i..	47%	21
NSNigella Sativa	46%	7
COColchicine	45%	3
AAAntiandrogen	44%	6
NONitric Oxide	44%	3
ZnZinc	41%	6
APAndrographol..	40%	4
V.CVitamin C	39%	7
BFBemnifosbuvir	38%	2
XNXXiannuoxin	38%	2
AZVAzvudine	37%	6
PBProbiotics	36%	6
BTBebtelovimab	34%	6
H2O2Hydrogen Per..	34%	3
QQuercetin	32%	4
SSotrovimab	29%	22
CCCurcumin	29%	11
NZNitazoxanide	29%	8
PTPhthalocyanine	29%	1
ENEnsitrelvir	26%	3
NACN-acetylcys..	21%	2
LRLeritrelvir	21%	2
PLPaxlovid	20%	52
PILPeg.. Lambda	17%	3